Navigation Links
Questcor Pharmaceuticals Issues Statement
Date:1/11/2012

ANAHEIM, Calif., Jan. 11, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) today announced it became aware that an investor blog is preparing to issue a report regarding the Company's marketing and business practices.  Questcor issued the following statement:

The Company believes that its marketing and business practices are consistent with regulatory requirements and industry standard practices.  Questcor markets H.P. Acthar® Gel for the treatment of acute exacerbations of multiple sclerosis (MS) in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age.  The Company maintains a compliance program, which is led by an experienced compliance officer and includes the active participation of Questcor's executive management team.  Questcor attributes its success to the ability of Acthar to potentially address the unmet medical need associated with MS exacerbations and nephrotic syndrome.  The Company is committed to providing access to Acthar to patients who need it, and marketing Acthar in accordance with regulatory requirements and industry standard practices.  Questcor plans to speak with the publication to discuss the Company and its marketing and business practices.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, diffi
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Questcor Reports Solid Fourth Quarter Results
2. Questcor to Discuss Results From FDA Panel Meeting
3. Trading Halted Today in Questcor Pharmaceuticals Common Stock
4. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
5. Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
6. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
7. Questcor to Present at UBS Global Life Sciences Conference
8. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
9. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
10. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
11. Questcor Reports Third Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
(Date:6/19/2013)... N.J. , June 19, 2013 /PRNewswire-iReach/ ... Pharma, a new specialty pharmaceutical company dedicated ... of innovative injectable and sustained release drug ... unmet medical needs, today announced the acquisition ... Linker Technology®) platform and associated product pipeline. ...
(Date:6/19/2013)... Calif. , June 19, 2013 ... management solutions, introduced the next-generation of its ... which allows health plans to provide their employer ... populations, health factors, medical and prescription drug claims, ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2
... May 11, 2011 Reportlinker.com announces ... is available in its catalogue: ... 2011 – Generics Market Overview: Patent ... uptake despite tougher market conditions ...
... Daiichi Sankyo announced that applications have been submitted ... of metastatic melanoma to the U.S. Food and Drug ... a pre-marketing application for approval for a companion diagnostic ... also will be registered in Europe.  Vemurafenib is an ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 2Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 3Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 4Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 5Vemurafenib New Drug Application Submitted to FDA for Melanoma 2Vemurafenib New Drug Application Submitted to FDA for Melanoma 3Vemurafenib New Drug Application Submitted to FDA for Melanoma 4
(Date:6/19/2013)... 19, 2013 Maui'd Forever , ... to being an effective and cost effective way to ... have partnered up with Tom Barefoot’s Tours providing an ... most of Hawaii’s activities. , They have just released ... get the lowest prices on their Hawaii activities. ...
(Date:6/19/2013)... 2013 According to Transparency Market Research ... Trends, Analysis and Forecast, 2011 – 2017,” the global ... the year 2011 and is expected to reach USD ... 9.7% from 2011 to 2017. Flexible endoscopes formed the ... USD 2,201 million for the year 2011. , Related ...
(Date:6/19/2013)... treating stroke victims has been "time equals brain." That,s because ... a drug that dissolves the stroke-causing blood clot can make ... or lost. , But specific information has been ... drug known as a tissue plasminogen activator, or tPA ... most common type of stroke. , Now, a ...
(Date:6/19/2013)... MAYWOOD, Il. A Loyola University Chicago Niehoff School ... grant to study whether Vitamin D can improve mood ... study also will examine whether vitamin D supplementation can ... their diabetes. The grant is from the National Institute ... , Principal investigator Sue M. Penckofer, PhD, RN and ...
(Date:6/19/2013)... AquaPrint Solutions in Thomson, IL is proud to ... newly-designed Harley Davidson motorcycle gas tank. A couple of weeks ... idea of taking a split tank motorcycle that had been ... into a work of art. , In October of ... seats that had been dipped in a water transfer printer ...
Breaking Medicine News(10 mins):Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:Loyola receives $1.5 million grant to study vitamin D for diabetes and depression 2Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2
... IL, April 7, 2009) Managing pain in the ICU ... team. However, new reports suggest that taking a comprehensive approach ... in the ICU and even decreasing the incidence of preventable ... CHEST , the peer-reviewed journal of the American College of ...
... for Usability Evaluation of HIT ProvidersCHICAGO, April 7 ... usability of Electronic Health Records (EHRs), User Centric ( ... performance research designed to provide end-users with real data ... the key limiting factors to adoption now is usability. ...
... designed to benefit individuals with autism and their ... America (ASA), the leading grassroots autism organization and ... medical information services, have teamed up to provide ... the spectrum and their families through the MedicAlert(R) ...
... Mass., April 7 Gene Network Sciences, Inc. today ... researcher in the field of genomics-driven drug discovery, co-chair ... be leaving his position as Executive Scientific ... forces with the departing head of Merck oncology, Dr. ...
... with the autoimmune disease systemic lupus erythematosus (SLE) is ... Hormones secreted by the body are therefore believed to ... disease. A new large, population-based observational study found that ... increased risk of SLE, particularly among women who had ...
... Coverage for RetireesJACKSONVILLE, Fla. , April 7 ... health care coverage to retirees, Blue Cross and ... Group Supplement insurance plans. BlueMedicare Group Supplement is ... who are 65 and older.(Logo: ...
Cached Medicine News:Health News:'Pain in the ICU' report suggests comprehensive approach 2Health News:'Pain in the ICU' report suggests comprehensive approach 3Health News:EMRs Put to the Test on Usability 2Health News:EMRs Put to the Test on Usability 3Health News:Autism Society of America Joins MedicAlert Foundation to offer MedicAlert(R) + Safe and Sound(R) - 24-Hour Comprehensive Protection System 2Health News:Gene Network Sciences Names Departing Merck Head of Genetics Eric Schadt as Co-Chair of Scientific Advisory Board 2Health News:Gene Network Sciences Names Departing Merck Head of Genetics Eric Schadt as Co-Chair of Scientific Advisory Board 3Health News:Oral contraceptives associated with increased risk of lupus 2Health News:Blue Cross and Blue Shield of Florida Introduces BlueMedicare(SM) Group Supplement 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: